Undisclosed SMARCA2 Degrader
/ Amphista Therap
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
September 17, 2025
Amphista Therapeutics discloses first details of its SMARCA2 degrader program
(GlobeNewswire)
- "Amphista has identified a series of SMARCA2 degraders that have demonstrated CNS penetration in vivo. This offers the potential to develop medicines which can treat CNS metastasis, which frequently occur in lung cancer....Amphista plans to present data from its SMARCA2 Targeted Glue program at a key forthcoming scientific conference."
Preclinical • Non Small Cell Lung Cancer • Solid Tumor
1 to 1
Of
1
Go to page
1